Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 728 across all filing types
Latest filing 2022-04-28 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
安永华明会计师事务所（特殊普通合伙）关于百济神州有限公司非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a specialized audit report issued by Ernst & Young Hua Ming LLP for BeiGene Ltd. It specifically addresses the non-operating fund occupation and other related party fund transactions for the fiscal year 2021. The document includes detailed tables summarizing these transactions and is dated April 27, 2022. It references the audit of the 2021 financial statements and provides a special explanation in compliance with regulatory guidelines for listed companies regarding fund transactions and guarantees. The document is not a full annual report but a standalone audit-related report focusing on a specific aspect of the company's financials. It is not a mere announcement or certification but contains substantive audited financial data related to the special audit. Therefore, it fits the category of an Audit Report / Information (AR). FY 2021
2022-04-28 Chinese
百济神州有限公司2021年度报告摘要
Annual Report Classification · 95% confidence The document is titled as "2021 年年度报告摘要" which translates to "2021 Annual Report Summary." It contains detailed information about the company's business, products, financial status, risk factors, and governance. The text includes comprehensive descriptions of the company's operations, product pipeline, clinical trials, and financial conditions for the fiscal year 2021. It also references the full annual report and audit opinions, indicating this is a summary of the full annual report. The document length is 15,000 characters, which is substantial and contains substantive financial and operational data, not just an announcement or a brief summary. Therefore, this document fits the definition of an Annual Report (10-K) rather than a mere announcement or other filing types. FY 2021
2022-04-28 Chinese
安永华明会计师事务所（特殊普通合伙）关于百济神州有限公司募集资金存放与使用情况的专项报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金存放与使用情况的专项报告" which translates to a "Special Report on the Deposit and Use of Raised Funds" for the year 2021. It includes detailed audited information about the company's fundraising, the amount raised, usage, management, and compliance with regulatory requirements. The report is prepared by an accounting firm (Ernst & Young Hua Ming LLP) and includes audit opinions and detailed financial tables related to the raised funds. It references regulatory guidelines specific to fundraising and capital management. The document is not a general annual report or earnings release but a specialized audit report focused on the use and management of raised capital. This fits the category of an Audit Report / Information (AR) as it is a standalone audit report on a specific aspect of the company's financials, not a full annual report or interim report. The document length is substantial and contains detailed financial data and audit opinions, confirming it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-04-28 Chinese
百济神州有限公司2021年度报告
Annual Report Classification · 100% confidence The document is titled '2021 年年度报告' which translates to '2021 Annual Report'. It contains detailed financial data, management discussion and analysis, company overview, risk factors, governance information, and audited financial statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes signatures from company officers and auditors, detailed financial metrics, and comprehensive sections typical of an annual report. Therefore, this document is classified as an Annual Report (10-K equivalent). FY 2021
2022-04-28 Chinese
中国国际金融股份有限公司、高盛高华证券有限责任公司关于百济神州有限公司2021年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report on the 2021 annual verification of the storage and use of raised funds by BeiGene Ltd. It includes specifics on the amount raised, the use and balance of the funds, management and regulatory compliance, and an auditor's attestation report from Ernst & Young Hua Ming LLP. The document references regulatory guidelines and includes a special report issued by the accounting firm on the use of the raised funds. This type of document is a standalone audit-related report focusing on the verification of fundraising proceeds and their usage, not a full annual report or earnings release. It fits the definition of an Audit Report / Information (AR) as it is a specialized audit opinion on fundraising usage and compliance, rather than a general financial report or announcement. FY 2021
2022-04-28 Chinese
百济神州有限公司2021年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2021年度募集资金存放与实际使用情况的专项报告" which translates to "2021 Annual Special Report on the Deposit and Actual Use of Raised Funds." It details the amount of funds raised through an IPO, the use and management of these funds, and includes audit opinions from an accounting firm and verification from joint sponsors. The document is comprehensive, contains financial figures, regulatory references, and audit conclusions specifically about the use of raised capital. This type of report is a specialized report on capital raising and fund usage, which aligns with the category of Capital/Financing Update (CAP). It is not a general annual report (10-K), nor an audit report (AR) since it focuses on fundraising and fund usage rather than full financial statements or audit opinions on financials. It is not a simple announcement or certification, but a detailed report on fundraising and capital usage. Therefore, the correct classification is CAP with high confidence.
2022-04-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.